HUP0102471A2 - 4-Benzil-piperidin alkilszulfoxid heterociklusok és használatuk altípus-szelektív NMDA antagonistaként és ezeket tartalmazó gyógyszerkészítmények - Google Patents
4-Benzil-piperidin alkilszulfoxid heterociklusok és használatuk altípus-szelektív NMDA antagonistaként és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0102471A2 HUP0102471A2 HU0102471A HUP0102471A HUP0102471A2 HU P0102471 A2 HUP0102471 A2 HU P0102471A2 HU 0102471 A HU0102471 A HU 0102471A HU P0102471 A HUP0102471 A HU P0102471A HU P0102471 A2 HUP0102471 A2 HU P0102471A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- hydroxy
- heterocycles
- hydrogen atom
- subtype
- Prior art date
Links
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- -1 hydroxy- Chemical class 0.000 abstract 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 2
- 150000001721 carbon Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 239000004090 neuroprotective agent Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A találmány tárgyát az (II) általános képletű 4-benzil-piperidinalkilszulfoxid heterociklusok képezik. A találmány szerinti vegyületekaz N-metil-D-aszpartát (NMDA) receptor altípusok szelektívantagonistái. A találmány tárgyát képezi továbbá a 4-benzil-piperidin-alkilszulfoxid heterociklusok használata neuroprotektív ágensként. A(II) általános képletű vegyület, vagy ennek sztereoizomerjei vagygyógyászatilag elfogadható sói, amikben R és R< jelentése egymástólfüggetlenül az alábbi csoportból választható: hidrogénatom, hidroxi-,alkilcsoport, halogénatom, nitro-, cianokarboxaldehid, aldehid-amin-,alacsonyabb szénatomszámú alkoxi karbonilmetil-, hidroxi alacsonyszénatomszámú alkil-, hidrazinokarbonilmetil-, acetamido-, aril-,aralkil-, amino-, halogénezett alkilcsoport, alacsony szénatomszámúalkilaminocsoport vagy alacsony szénatomszámú alkoxicsoport; R< ésR''' egymástól függetlenül az alábbi csoportból választható:hidrogénatom, hidroxi-, alkilcsoport, halogénatom, aminocsoport,halogénezett alkilcsoport, alacsonyabb szénatomszámú aminocsoport vagyalacsonyabb szénatomszámú alkoxicsoport; X jelentése hidrogénatom vagyhidroxicsoport; Z jelentése -CH2- vagy O || -C- n értéke 2-4 között van; és Y jelentése O, NH vagy S. A találmánytárgya továbbá az (II) általános képletű vegyületeket tartalmazógyógyszerkészítményekre és azok alkalmazására is kiterjed. A találmányszerinti vegyületeknek egy különösen előnyös használata a Parkinson-kór kezelése. Ó
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9091498P | 1998-06-26 | 1998-06-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0102471A2 true HUP0102471A2 (hu) | 2002-05-29 |
Family
ID=22224939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0102471A HUP0102471A2 (hu) | 1998-06-26 | 1999-06-25 | 4-Benzil-piperidin alkilszulfoxid heterociklusok és használatuk altípus-szelektív NMDA antagonistaként és ezeket tartalmazó gyógyszerkészítmények |
Country Status (28)
Country | Link |
---|---|
US (1) | US6284774B1 (hu) |
EP (1) | EP1089735B1 (hu) |
JP (1) | JP2002519322A (hu) |
KR (1) | KR20010053170A (hu) |
CN (1) | CN1304307A (hu) |
AP (1) | AP2000001949A0 (hu) |
AT (1) | ATE297207T1 (hu) |
AU (1) | AU769650B2 (hu) |
BG (1) | BG105082A (hu) |
BR (1) | BR9911575A (hu) |
CA (1) | CA2327888A1 (hu) |
DE (1) | DE69925730T2 (hu) |
EA (1) | EA200100058A1 (hu) |
EE (1) | EE200000778A (hu) |
ES (1) | ES2244201T3 (hu) |
HU (1) | HUP0102471A2 (hu) |
ID (1) | ID28005A (hu) |
IL (1) | IL138949A0 (hu) |
IS (1) | IS5667A (hu) |
NO (1) | NO20006482D0 (hu) |
NZ (1) | NZ508808A (hu) |
OA (1) | OA11570A (hu) |
PE (1) | PE20000728A1 (hu) |
PL (1) | PL345024A1 (hu) |
SK (1) | SK19512000A3 (hu) |
TR (1) | TR200003888T2 (hu) |
WO (1) | WO2000000197A1 (hu) |
ZA (1) | ZA200005848B (hu) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6476041B1 (en) * | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
UA73749C2 (en) * | 1999-11-01 | 2005-09-15 | Diarylenines | |
CZ20023479A3 (cs) * | 2000-04-26 | 2003-04-16 | Warner-Lambert Company | Cyklohexylaminový derivát, jako subtyp selektivních antagonistů NMDA receptoru |
US6765022B2 (en) | 2000-06-01 | 2004-07-20 | Warner-Lambert Company | Cyclohexylamine derivatives as subtype selective nmda receptor antagonists |
EP1304324B1 (en) * | 2000-07-18 | 2007-10-03 | Dainippon Sumitomo Pharma Co., Ltd. | Serotonin reuptake inhibitors |
IL145584A0 (en) * | 2000-10-02 | 2002-06-30 | Pfizer Prod Inc | Nmda nr2b antagonists for treatment |
HU227197B1 (en) | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
IL157254A0 (en) | 2001-02-23 | 2004-02-19 | Merck & Co Inc | N-substituted nonaryl-heterocyclic nmda/mr2b antagonists |
US7375136B2 (en) * | 2001-03-08 | 2008-05-20 | Emory University | pH-dependent NMDA receptor antagonists |
WO2002080928A1 (en) | 2001-04-03 | 2002-10-17 | Merck & Co., Inc. | N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists |
CA2381630A1 (en) * | 2001-04-23 | 2002-10-23 | Leonard Theodore Meltzer | Method for preventing dyskinesias |
PL216636B1 (pl) | 2001-07-24 | 2014-04-30 | Richter Gedeon Vegyészeti Gyár RT | Pochodne amidów kwasów karboksylowych, środek farmaceutyczny, sposób wytwarzania pochodnych amidów kwasów karboksylowych, sposób wytwarzania środka farmaceutycznego i zastosowanie pochodnych amidów kwasów karboksylowych |
US20030211040A1 (en) | 2001-08-31 | 2003-11-13 | Paul Greengard | Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain |
US20060281797A1 (en) * | 2001-12-11 | 2006-12-14 | University Of Virginia Patent Foundation | Neurorestoration with R(+) Pramipexole |
ATE480235T1 (de) * | 2001-12-11 | 2010-09-15 | Univ Virginia | Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose |
US20040082543A1 (en) * | 2002-10-29 | 2004-04-29 | Pharmacia Corporation | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
CA2588296A1 (en) | 2004-11-24 | 2006-06-01 | Neuromolecular Pharmaceuticals, Inc. | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease |
EP2425845A1 (en) * | 2004-12-23 | 2012-03-07 | Voyager Pharmaceutical Corporation | Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease |
JP2009504748A (ja) * | 2005-08-15 | 2009-02-05 | ユニバーシティ オブ バージニア パテント ファウンデーション | R(+)プラミペキソールを用いた神経回復 |
US8518926B2 (en) | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
KR20090021169A (ko) | 2006-05-16 | 2009-02-27 | 크놉 뉴로사이언시스 인코포레이티드 | R(+) 및 s(-) 프라미펙솔을 포함하는 조성물 및 이의 사용 방법 |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
US8524695B2 (en) | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
CN101668525A (zh) | 2007-03-01 | 2010-03-10 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶抑制剂的新用途 |
WO2008113056A2 (en) | 2007-03-14 | 2008-09-18 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
EP2142514B1 (en) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
AU2008272964A1 (en) * | 2007-06-29 | 2009-01-08 | Emory University | NMDA receptor antagonists for neuroprotection |
DE102007047737A1 (de) | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
TWI410420B (zh) * | 2008-02-05 | 2013-10-01 | Dainippon Sumitomo Pharma Co | 苄基哌啶化合物 |
EP2273988B1 (en) | 2008-04-18 | 2015-09-09 | Arizona Board Of Regents, A Body Corp. Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona | L-dopa for treating age-related macular degeneration |
EP2334185A4 (en) | 2008-08-19 | 2011-09-21 | Knopp Neurosciences Inc | COMPOSITIONS AND METHODS FOR USE OF (R) -PRAMIPEXOL |
HUP0900130A3 (en) | 2009-03-03 | 2012-02-28 | Richter Gedeon Nyrt | Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation |
AU2010279963A1 (en) | 2009-08-04 | 2012-02-23 | Dainippon Sumitomo Pharma Co., Ltd. | Benzyl piperidine compound |
EP2461673A4 (en) | 2009-08-05 | 2013-08-07 | Intra Cellular Therapies Inc | NEW REGULATOR PROTEINS AND HEMMER |
SG178953A1 (en) | 2009-09-11 | 2012-04-27 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
BR112012013487A2 (pt) | 2009-12-02 | 2017-10-03 | Adamas Pharmaceuticals Inc | Composições de amantadina e métodos de uso |
ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
RU2638807C2 (ru) | 2011-11-22 | 2017-12-15 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Способы и композиции для лечения воспаления и ишемического поражения |
WO2013096816A1 (en) | 2011-12-22 | 2013-06-27 | Biogen Idec Ma Inc. | Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
US10154971B2 (en) | 2013-06-17 | 2018-12-18 | Adamas Pharma, Llc | Methods of administering amantadine |
PL3019167T3 (pl) | 2013-07-12 | 2021-06-14 | Knopp Biosciences Llc | Leczenie podwyższonych poziomów eozynofili i/lub bazofili |
US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
ES2813674T3 (es) | 2013-08-13 | 2021-03-24 | Knopp Biosciences Llc | Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b |
HUE055850T2 (hu) | 2013-08-13 | 2022-01-28 | Knopp Biosciences Llc | Készítmények és módszerek a krónikus urticaria (csalánkiütés) kezelésére |
WO2016100940A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute, Inc. | Dopamine d2 receptor ligands |
US10752588B2 (en) | 2014-12-19 | 2020-08-25 | The Broad Institute, Inc. | Dopamine D2 receptor ligands |
BR112020003375A2 (pt) | 2017-08-24 | 2020-08-25 | Adamas Pharma, Llc | composições de amantadina, preparações das mesmas, e métodos de uso |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
EP3958973A4 (en) * | 2019-04-26 | 2023-06-07 | Cytosolve, Inc. | COMPOSITIONS TO IMPROVE BRAIN HEALTH AND MEMORY |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE792187A (fr) * | 1971-12-03 | 1973-03-30 | Sumitomo Chemical Co | Nouveaux derives d'alkylamines |
DE2845537A1 (de) * | 1978-10-19 | 1980-04-30 | Bayer Ag | Benzimidazolylcarbamidsaeureester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
ZA848275B (en) * | 1983-12-28 | 1985-08-28 | Degussa | New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring |
EP0488959A3 (en) | 1990-11-28 | 1992-08-05 | Sandoz Ltd. | New uses of competitive nmda receptor antagonists |
JPH05194505A (ja) * | 1991-08-09 | 1993-08-03 | Yoshitomi Pharmaceut Ind Ltd | チオフェン化合物 |
US5192751A (en) | 1992-07-24 | 1993-03-09 | Eli Lilly And Company | Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence |
JP2959615B2 (ja) * | 1993-06-24 | 1999-10-06 | 吉富製薬株式会社 | 縮合型チオフェン化合物およびその医薬用途 |
DK0709384T3 (da) | 1994-10-31 | 1999-08-23 | Merck Patent Gmbh | Benzylpiperidinderivater med høj affinitet til aminosyrereceptorers bindingssteder |
WO1996031471A1 (en) * | 1995-04-07 | 1996-10-10 | Novo Nordisk A/S | Novel method |
ZA9610745B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
ZA9610741B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
AU4376997A (en) * | 1996-10-04 | 1998-05-05 | Novo Nordisk A/S | N-substituted azaheterocyclic compounds |
DE19643790A1 (de) | 1996-10-30 | 1998-05-07 | Merck Patent Gmbh | Benzoxazol-Derivat |
-
1999
- 1999-06-24 PE PE1999000567A patent/PE20000728A1/es not_active Application Discontinuation
- 1999-06-25 CN CN99807087A patent/CN1304307A/zh active Pending
- 1999-06-25 AT AT99931887T patent/ATE297207T1/de not_active IP Right Cessation
- 1999-06-25 US US09/674,298 patent/US6284774B1/en not_active Expired - Fee Related
- 1999-06-25 JP JP2000556782A patent/JP2002519322A/ja active Pending
- 1999-06-25 BR BR9911575-1A patent/BR9911575A/pt not_active Application Discontinuation
- 1999-06-25 OA OA1200000347A patent/OA11570A/en unknown
- 1999-06-25 HU HU0102471A patent/HUP0102471A2/hu unknown
- 1999-06-25 ES ES99931887T patent/ES2244201T3/es not_active Expired - Lifetime
- 1999-06-25 ID IDW20002514A patent/ID28005A/id unknown
- 1999-06-25 DE DE69925730T patent/DE69925730T2/de not_active Expired - Fee Related
- 1999-06-25 AU AU48303/99A patent/AU769650B2/en not_active Ceased
- 1999-06-25 CA CA002327888A patent/CA2327888A1/en not_active Abandoned
- 1999-06-25 PL PL99345024A patent/PL345024A1/xx unknown
- 1999-06-25 IL IL13894999A patent/IL138949A0/xx unknown
- 1999-06-25 WO PCT/US1999/014291 patent/WO2000000197A1/en active IP Right Grant
- 1999-06-25 KR KR1020007014745A patent/KR20010053170A/ko not_active Application Discontinuation
- 1999-06-25 TR TR2000/03888T patent/TR200003888T2/xx unknown
- 1999-06-25 EP EP99931887A patent/EP1089735B1/en not_active Expired - Lifetime
- 1999-06-25 EA EA200100058A patent/EA200100058A1/ru unknown
- 1999-06-25 EE EEP200000778A patent/EE200000778A/xx unknown
- 1999-06-25 AP APAP/P/2000/001949A patent/AP2000001949A0/en unknown
- 1999-06-25 SK SK1951-2000A patent/SK19512000A3/sk unknown
- 1999-06-25 NZ NZ508808A patent/NZ508808A/xx unknown
-
2000
- 2000-10-16 IS IS5667A patent/IS5667A/is unknown
- 2000-10-19 ZA ZA200005848A patent/ZA200005848B/en unknown
- 2000-12-19 NO NO20006482A patent/NO20006482D0/no not_active Application Discontinuation
- 2000-12-21 BG BG105082A patent/BG105082A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
PE20000728A1 (es) | 2000-08-21 |
DE69925730D1 (de) | 2005-07-14 |
CA2327888A1 (en) | 2000-01-06 |
BG105082A (en) | 2001-09-28 |
IS5667A (is) | 2000-10-16 |
ES2244201T3 (es) | 2005-12-01 |
JP2002519322A (ja) | 2002-07-02 |
DE69925730T2 (de) | 2006-03-23 |
OA11570A (en) | 2004-07-01 |
EE200000778A (et) | 2002-04-15 |
WO2000000197A1 (en) | 2000-01-06 |
AU4830399A (en) | 2000-01-17 |
SK19512000A3 (sk) | 2001-08-06 |
NO20006482L (no) | 2000-12-19 |
EP1089735B1 (en) | 2005-06-08 |
ID28005A (id) | 2001-05-03 |
NO20006482D0 (no) | 2000-12-19 |
EA200100058A1 (ru) | 2001-08-27 |
NZ508808A (en) | 2002-12-20 |
AP2000001949A0 (en) | 2000-12-31 |
IL138949A0 (en) | 2001-11-25 |
EP1089735A1 (en) | 2001-04-11 |
TR200003888T2 (tr) | 2001-06-21 |
KR20010053170A (ko) | 2001-06-25 |
EP1089735A4 (en) | 2002-12-18 |
ZA200005848B (en) | 2001-12-18 |
AU769650B2 (en) | 2004-01-29 |
BR9911575A (pt) | 2001-03-20 |
CN1304307A (zh) | 2001-07-18 |
ATE297207T1 (de) | 2005-06-15 |
US6284774B1 (en) | 2001-09-04 |
PL345024A1 (en) | 2001-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0102471A2 (hu) | 4-Benzil-piperidin alkilszulfoxid heterociklusok és használatuk altípus-szelektív NMDA antagonistaként és ezeket tartalmazó gyógyszerkészítmények | |
HUP0204283A2 (hu) | (Kinolil-propil)-piperidin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HK1068334A1 (en) | Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments | |
HUP0303756A2 (hu) | 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények | |
IL133825A0 (en) | Substituted 6-phenylphenanthridines, medicaments containing same and use thereof | |
HUP0301690A2 (hu) | Szinergikus eljárások és készítmények rák kezelésére | |
AP2001002241A0 (en) | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents. | |
ATE289602T1 (de) | Quinolin-2-on-derivate verwendbar als antikrebsmittel | |
GB9914486D0 (en) | Medicaments | |
TW200420542A (en) | A compound having TGF β inhibition activity and a medicinal composition containing the same | |
MY132872A (en) | Benzimidazole derivatives. | |
ATE304019T1 (de) | Inhibitoren des nukleosid-metabolismus | |
MA26861A1 (fr) | Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires | |
PL315636A1 (en) | Cosmetic or pharmaceutic compositions containing magnipherine or its derivatives | |
MXPA04000577A (es) | Derivados de dolastatina 10. | |
AP1541A (en) | New thiadazoles and oxadiazoles and their use as phosphodiesterase - 7 inhibitors. | |
AP1816A (en) | 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists. | |
HUP0100865A2 (hu) | Meta-azaciklusos csoporttal N-szubsztituált amino-benzoesav-vegyületek és származékaik mint integrin antagonista hatóanyagok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
TW200504085A (en) | Derivatives of [2-(8,9-dioxo-2, 6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and methods of use thereof | |
ATE233754T1 (de) | Diphenyl-piperidin derivate | |
HUP0002929A2 (hu) | Tachikinin receptor antagonista hatású 2-acilamino-propán-aminok és az ezeket tartalmazó gyógyszerkészítmények | |
ATE238274T1 (de) | Naphthalin derivate | |
PL334088A1 (en) | Novel derivatives of n-benzenesulphonyl-l-proline, methods of obtaining them and pharmaceutic agents | |
HUP0302255A2 (hu) | Szulfonamidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
AP9901559A0 (en) | Tricyclic 3-keto derivatives of 6-0-methylerythromycin. |